Dimerix (ASX:DXB) secured non-dilutive loan facility agreements with a syndicate of Australian and US-based lenders to access up to AU$34 million, according to a Friday Australian bourse filing.
This included a previously announced initial facility agreement of AU$10 million with Skiptan, per the filing. The firm confirmed that it was funded through to completion of the Action3 phase 3 trial in DMX-200, as well as the planned phase 2 clinical trial in DMX-652.
The facility carries an interest rate of 10% per year, compounding annually, the company said. The receipt of the initial 50% draw-down is anticipated by Sept. 18, and the remainder is expected to take place at the firm's discretion on or before March 31, 2027.
The facility provides the flexibility for Dimerix to elect to take further commitments for up to a total of AU$50 million on or before March 31, 2027.
The biopharmaceutical company's shares were up 4% in recent Friday trade.